Nathalie Garcon
Rixensart, WAL, Belgium
Last Updated: 09/26/2026
Save publications for later
Sign Up
Not sure about your diagnosis?
Check Your Symptoms
Found 41 publications
Safety and immunogenicity of a cytomegalovirus (CMV) recombinant glycoprotein B (gB) vaccine in combination with polyacrylate or an emulsion-based adjuvants.
Journal: Vaccine
Published: January 10, 2026
The success of toll-like receptor 4 based vaccine adjuvants.
Journal: Vaccine
Published: December 04, 2024
Antibody avidity, persistence, and response to antigen recall: comparison of vaccine adjuvants.
Journal: NPJ vaccines
Published: July 08, 2020
Safety biomarkers for development of vaccines and biologics: Report from the safety biomarkers symposium held on November 28-29, 2017, Marcy l'Etoile, France.
Journal: Vaccine
Published: February 10, 2020
The science of vaccine safety: Summary of meeting at Wellcome Trust.
Journal: Vaccine
Published: August 20, 2019
Safety of AS03-adjuvanted influenza vaccines: A review of the evidence.
Journal: Vaccine
Published: June 07, 2018
Erratum: Author Correction: Cellular and molecular synergy in AS01-adjuvanted vaccines results in an early IFNγ response promoting vaccine immunogenicity.
Journal: NPJ vaccines
Published: March 28, 2018
Different Adjuvants Induce Common Innate Pathways That Are Associated with Enhanced Adaptive Responses against a Model Antigen in Humans.
Journal: Frontiers in immunology
Published: April 19, 2017
Signal management in pharmacovigilance and human risk assessment of CpG 7909, integrating embryo-fetal and post-natal developmental toxicity studies in rats and rabbits.
Journal: Reproductive toxicology (Elmsford, N.Y.)
Published: February 17, 2017
Cellular and molecular synergy in AS01-adjuvanted vaccines results in an early IFNγ response promoting vaccine immunogenicity.
Journal: NPJ vaccines
Published: November 10, 2016
From discovery to licensure, the Adjuvant System story.
Journal: Human vaccines & immunotherapeutics
Published: September 17, 2016
Last Updated: 09/26/2026